MediWound Ltd. reported that a prospective study published in the Journal of Burn Care & Research demonstrates its enzymatic debridement product, NexoBrid, can reduce pigment and embedded particles in traumatic tattoo wounds by 92.5%. The study, conducted at Sheba Medical Center’s National Burn Center, enrolled 15 patients with friction or blast injuries and measured the mean pigmented wound area before treatment (37.5 %) and after treatment (2.1 %). The 92.5 % reduction was driven by a 96 % improvement in abrasive injuries and an 84 % improvement in explosive injuries, with no treatment‑related adverse events reported.
The data were collected within 24 hours of injury and applied at bedside under procedural sedation, underscoring the product’s rapid, selective enzymatic action on damaged skin layers. Professor Josef Haik, Director of the Department of Plastic and Reconstructive Surgery and Burn Center at Sheba, noted that the selective enzymatic action “helps remove many of the particles embedded within the damaged layers,” explaining the high efficacy observed in the study.
MediWound’s clinical data support a strategic expansion of NexoBrid’s indications beyond its current FDA‑approved use for eschar removal in thermal burns. The company’s Q3 2025 financial results—revenue of $5.4 million, up 23 % year‑over‑year, and a net loss of $2.7 million ($0.24 per share)—highlight a growing revenue base that could absorb the incremental sales from a new indication. The company’s strong cash position and recent commissioning of an expanded manufacturing facility position it to meet potential demand for the expanded product line.
The study’s small sample size and short follow‑up period limit definitive conclusions about long‑term cosmetic outcomes, and MediWound has indicated that larger, controlled studies are needed to confirm the durability of the results. Nonetheless, the data provide a compelling early signal that NexoBrid can effectively debride traumatic tattoo wounds, potentially opening a new market segment and reinforcing MediWound’s competitive advantage in the enzymatic wound‑care market.
MediWound also continues to advance its pipeline with EscharEx, an investigational therapy for chronic wound debridement, and a Phase III trial (VALUE) is underway. The company’s recent manufacturing expansion and the positive clinical data together suggest a trajectory of product portfolio growth and market penetration beyond traditional burn care.
The study’s publication on December 10 2025 marks a significant milestone for MediWound, offering a new therapeutic pathway that could translate into additional revenue streams and strengthen its position as a leader in enzymatic wound‑care solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.